A Combination of Talazoparib and Enzalutamide Prolongs OS in Unselected and Patients with HRR-deficient mCRPC By Ogkologos - August 11, 2025 598 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the TALAPRO-2 study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC Patient Guide in Soft Tissue Sarcoma Now Available Also in Ukrainian Adjuvant Pembrolizumab Continues to Demonstrate Benefit in DFS and OS Among Patients with ccRCC MOST POPULAR What Happens If More People Get Screened for Cancer? January 26, 2024 Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 Keeping progress in oncology on the agenda: ESMO honours recipients of... December 3, 2020 Combination Therapy with Venetoclax Approved for Chronic Lymphocytic Leukemia June 17, 2019 Load more HOT NEWS Quarantined Cruise Ship Passenger Concerned She Won’t Make It Home for... New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... Adagrasib Demonstrates Clinical Activity Across a Broad Range of Tumour Types... Adding Blinatumomab to Consolidation Chemotherapy Improves OS in Adult Patients in...
